The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis

Author(s):
Engels, C.C.; Kiderlen, M.; Bastiaannet, E.; Eijk, R. van; Mooyaart, A.; Smit, V.T.H.B.M. (0000-0003-3730-5652); Craen, A.J.M. de (0000-0001-9314-123X); Kuppen, P.J.K. (0000-0002-0294-3251); Kroep, J.R.; Velde, C.J.H. van de (0000-0003-0104-1800); Liefers, G.J.
Published
2016
Publication type
Article / Letter to editor
Breast cancerGeriatric oncologyEpidemiologyPrognostic markersHER-2PIK3CACompeting riskAnti-HER2 therapy
Date issued
2016-04-30
Language
English
Is part of
Breast Cancer Research and Treatment (2016), Vol. 156, no. 2, p. 361-370
hdl
1887/112940
doi
10.1007/s10549-016-3734-y